Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21553986 | 0.99 | AKT1 (0.42) | AKT1FAAHNPC1L3MBTL1GRIA1 | |
| SCHEMBL20241617 | 0.94 | AKT1 (0.46) | AKT1FAAHNPC1L3MBTL1 | |
| SCHEMBL20241812 | 0.94 | AKT1 (0.47) | AKT1FAAHNPC1L3MBTL1 | |
| SCHEMBL20242429 | 0.92 | FAAH (0.39) | AKT1FAAHGRIA1MMP9MMP8 | |
| SCHEMBL20242430 | 0.92 | FAAH (0.39) | AKT1FAAHGRIA1MMP9MMP8 | |
| SCHEMBL20257434 | 0.91 | L3MBTL1 (0.40) | FAAHNPC1L3MBTL1 | |
| SCHEMBL20241624 | 0.91 | FAAH (0.38) | AKT1FAAHGRIA1MMP9MMP8 | |
| SCHEMBL20241625 | 0.91 | FAAH (0.38) | AKT1FAAHGRIA1MMP9MMP8 | |
| SCHEMBL21553895 | 0.91 | AKT1 (0.40) | AKT1NPC1L3MBTL1MMP9MMP8 | |
| SCHEMBL21528419 | 0.90 | AKT1 (0.42) | AKT1FAAHNPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696639-B2 | Heterocyclic compounds as HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190337902-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696639-B2 | Heterocyclic compounds as HIV protease inhibitors | PREP, SERPINB1, PEPD | AKT1 1652/4885FAAH 629/4885NPC1 391/4885 |
| US-20190337902-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | PREP, SERPINB1, PEPD | AKT1 1652/4885FAAH 629/4885NPC1 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.